Comparative Cardiovascular Outcomes and Safety Profiles of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Trials.

Cureus · 2026 · PMC13418259 · PMID 42529614

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

EXSCEL reported a nominally significant reduction in all-cause mortality (HR: 0.86, 95% CI: 0.77-0.97) despite a neutral primary efficacy result [ 17 ], and PIONEER 6 showed lower cardiovascular and all-cause mortality (all-cause death, HR: 0.51, 95% CI: 0.31-0.84), albeit on a small number of events [ 19 ].

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.